Role of Zinc in the Development/Progression of Alcoholic Liver Disease.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert opinion without systematic review methodology or new human trial data
PubMed 28447197 · doi:10.1007/s11938-017-0132-4
What was done
This narrative review summarizes evidence on zinc metabolism, zinc dyshomeostasis mechanisms (poor intake/absorption, increased excretion, altered ZIP14 transporters), pathogenic roles in disease progression (intestinal barrier dysfunction, hepatocyte apoptosis), and experimental and clinical supplementation in alcoholic liver disease (ALD).
What was found
The abstract reports no numerical data, effect sizes, or statistical findings. It qualitatively describes zinc deficiency as an early feature in ALD pathogenesis and notes that zinc supplementation effectively corrects these mechanisms in experimental models. The authors report their clinical practice of administering daily oral zinc sulfate (220 mg, containing 50 mg elemental zinc) to patients with ALD.
Why it matters
With no FDA-approved pharmaceutical therapies for ALD, understanding nutritional mechanisms like zinc deficiency provides a low-cost, targeted supportive management strategy for alcohol-related liver and gut injury.
Limits
The review is narrative and non-systematic, offering clinical opinion rather than controlled trial data. The abstract cites no human sample sizes, effect sizes, clinical outcomes, or safety data, relying substantially on experimental (animal) models.
Cited by
- supports Alcohol consumption reduces intestinal zinc absorption and increases urinary zinc excretion.